Combining Proteomic Strategies and Molecular Display Technology for Development of Vaccines against Candida albicans
- *Corresponding Author:
- Seiji Shibasaki
General Education Center
Hyogo University of Health Sciences
Chuo-ku, Kobe 650-8530, Japan
E-mail: [email protected]
Received Date: May 26, 2014; Accepted Date: June 18, 2014; Published Date: June 23, 2014
Citation: Shibasaki S, Karasaki M, Ueda M (2014) Combining Proteomic Strategies and Molecular Display Technology for Development of Vaccines against Candida albicans. J Proteomics Bioinform 7:134-138. doi: 10.4172/jpb.1000313
Copyright: © 2014 Shibasaki S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recent developments in pharmaceutical technology allow systematic investigation of molecules operating in a living cell, facilitating identification of key players, which show potential as novel drug targets. One of the tools that has emerged for identifying potential antigens for use as vaccines against infectious diseases is time-course proteome analysis. The model virulent microorganism Candida albicans has been well studied in terms of both physiological characteristics and clinical aspects for developing pharmaceutics in treatments. In this article, we review a time-course proteome study of C. albicans during adaptation to a serum. Furthermore, we introduce a novel biotechnological strategy for developing vaccines using characteristic proteins that have been identified as virulence-related molecules.